Plain-English translation of NCT07428707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)—both blood cancers that haven't been treated before. Researchers want to understand how this medication affects your immune system by studying your blood and lymph node cells at different points during treatment. This is an early-stage study designed to gather information about how the medication works in your body.
While has shown promise in other studies, doctors don't yet fully understand how it changes the immune cells that fight cancer. This research will help doctors predict which patients are most likely to benefit from the treatment and potentially improve how it's used in the future.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once each day in 28-day cycles and continue until your cancer progresses, you experience unacceptable side effects, or you meet another stopping point. You would have lymph node biopsies and blood draws at the beginning and during treatment so researchers can study how your immune cells are changing. You would also be monitored for safety and how well the medication is working.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States